| Metric | H2 FY26 | H1 FY26 | H2 FY25 |
|---|---|---|---|
| Revenue from operations | 31.8 | 38.4 | 35.0 |
| Other income | -0.3 | 0.4 | 0.1 |
| Total income | 31.5 | 38.8 | 35.1 |
| Profit before exceptional items & tax | 1.5 | 0.8 | 1.0 |
| Profit before tax | 1.5 | 0.8 | 1.0 |
| Net profit | 1.0 | 0.6 | 0.7 |
| Operating margin | 4.8% | 2.1% | 2.8% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +42.90% |
|---|---|
| Net profit, quarter on quarter | +66.70% |
| Revenue, year on year | -9.10% |
NSE results filing, NSE: SAROJA. Figures extracted from the filing.
Saroja Pharma Industries India Ltd: key numbers
- Share price
- ₹40.80
- Market cap
- ₹16.40 Cr
- Revenue (annual)
- ₹70.13 Cr
- Net profit (annual)
- ₹1.62 Cr
- P/E (TTM)
- 10.1×Sector 37.2×
- Promoter holding
- 73.02%
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Saroja Pharma Industries India Ltd
All →Saroja Pharma Industries India Management Change
Saroja Pharma Industries India Limited appointed Mr. Ravindra Shivaji Salaskar as Chief Financial Officer. He currently serves as a Whole-time Director of the company.
Saroja Pharma Industries India Annual General Meeting
Saroja Pharma Industries India Limited has issued a notice for its 8th Annual General Meeting, scheduled to be held on September 30, 2026, through video conferencing.
Saroja Pharma Industries India Board Meeting Outcome
Saroja Pharma Industries approved its draft Board Report, Management Discussion and Analysis Report, and the notice for its 8th Annual General Meeting.
Saroja Pharma Industries India Board Meeting Outcome
Saroja Pharma announced the re-designation of Mr. Pulinattu Damodaran Nandakumar as Whole-time Director and the appointment of Mr. Niraj Variava as Internal Auditor.
Saroja Pharma Industries India Fund Raise of ₹9.11 Cr
Saroja Pharma confirms zero deviation in utilizing ₹9.11 Crore raised via IPO. The funds were fully deployed for manufacturing setup, debt repayment, and issue expenses.
- Value
- ₹9.11 Cr
Saroja Pharma Industries India Other Announcement
Saroja Pharma Industries India Limited submitted its annual SDD compliance certificate for FY2026. The auditor confirmed full compliance with SEBI insider trading database requirements.